As GLP-1 medications continue to reshape obesity treatment, many patients who are currently taking Wegovy are asking whether they can switch to Zepbound and what dose they should start with.

At first glance, converting between the two medications may seem simple. Both are weekly injections designed to support weight loss, reduce appetite, and improve metabolic health. However, Wegovy and Zepbound are not the same medication, and there is no official dose-for-dose conversion chart.

Wegovy contains semaglutide, while Zepbound contains tirzepatide. Although both medications affect the GLP-1 pathway, tirzepatide works through an additional mechanism by activating the GIP receptor. Because of these differences, switching requires a personalized approach rather than a simple mathematical conversion.

The closest comparison comes from clinical trial data showing similar weight-loss outcomes at certain doses. However, these comparisons represent average results across groups of patients, not guaranteed results for every individual.

Why a Direct Wegovy to Zepbound Conversion Does Not Exist

The biggest misconception about switching between these medications is that one dose of Wegovy equals a specific dose of Zepbound.

That comparison does not exist because the medications work differently at the biological level.

Different Active Ingredients and Mechanisms

Wegovy uses semaglutide, a GLP-1 receptor agonist. It works by mimicking the natural hormone GLP-1, which helps regulate appetite, slow stomach emptying, and improve insulin response.

Zepbound uses tirzepatide, a dual GIP and GLP-1 receptor agonist. In addition to activating GLP-1 receptors, it stimulates GIP receptors, creating another pathway involved in insulin regulation, appetite control, and metabolism.

These medications differ in:

• Molecular structure

• Receptor activity

• Binding strength

• Half-life

• Biological effects

Semaglutide has a half-life of about seven days, while tirzepatide has a half-life of approximately five days. Their different mechanisms mean that a higher number on one medication does not automatically mean it is stronger than another.

For example, Zepbound 10 mg is not simply “twice as strong” as Wegovy 5 mg. The doses cannot be directly compared in that way.

Wegovy and Zepbound Starting and Maintenance Doses

The FDA-approved dosing schedules show why direct conversion is not possible.

Wegovy Dosing Schedule

Wegovy gradually increases over several months:

• 0.25 mg weekly starting dose

• 0.5 mg weekly

• 1 mg weekly

• 1.7 mg weekly

• 2.4 mg weekly maintenance dose

The gradual increase helps the body adjust and reduces gastrointestinal side effects.

Zepbound Dosing Schedule

Zepbound follows a similar gradual approach:

• 2.5 mg weekly starting dose

• 5 mg weekly

• 7.5 mg weekly

• 10 mg weekly

• 12.5 mg weekly

• 15 mg weekly maximum dose

The starting doses are not equivalent. A person taking the highest Wegovy dose should not automatically begin at a higher Zepbound dose.

What Clinical Trials Show About Wegovy and Zepbound Weight Loss

Since there is no official conversion chart, researchers compare results from major clinical trials to estimate similar effectiveness.

The STEP trials evaluated semaglutide, while the SURMOUNT trials evaluated tirzepatide.

Medication

Weekly Dose

Average Weight Loss at 72 Weeks

Wegovy (semaglutide)

2.4 mg

About 14.9%

Zepbound (tirzepatide)

5 mg

About 15.0%

Zepbound (tirzepatide)

10 mg

About 19.5%

Zepbound (tirzepatide)

15 mg

About 20.9%

Based on these results, Zepbound 5 mg produces weight-loss results similar to Wegovy 2.4 mg in clinical trial populations.

Higher Zepbound doses produced greater average weight reduction compared with Wegovy’s maximum dose.

However, similar average results do not mean patients should switch using a fixed formula.

The Difference Between Equivalency and Conversion

A weight-loss comparison is not the same thing as a medication conversion.

A patient switching from Wegovy 2.4 mg to Zepbound 5 mg may experience:

• Similar appetite control

• More weight loss

• Less weight loss

• More side effects

• Fewer side effects

Individual results depend on many factors, including:

• Genetics

• Insulin sensitivity

• Starting weight

• Treatment duration

• Lifestyle habits

• Previous response to GLP-1 therapy

The goal is not to match milligrams. The goal is to find the lowest effective dose that provides meaningful results with manageable side effects.

How Doctors Typically Switch Patients From Wegovy to Zepbound

Switching should be planned with a healthcare provider. The process usually involves several steps.

Step 1: Determine Why the Switch Is Needed

A switch may make sense for reasons such as:

• Limited weight loss after several months on Wegovy

• Insurance coverage changes

• Ongoing side effects

• Desire for a medication with potentially greater weight-loss effects

However, switching too early may not be beneficial.

Changing medications after only a few weeks may not provide enough time to evaluate Wegovy’s full effect.

Step 2: Decide When to Start Zepbound After Wegov

Providers generally consider two approaches.

The Washout Approach

This is the more common strategy.

Typical process:

1. Take the final Wegovy injection

2. Wait approximately 7 to 10 days

3. Begin Zepbound at the starting dose

Advantages:

• Less overlap between medications

• Lower chance of excessive nausea

• Easier to identify side effects

The disadvantage is that some patients may notice increased hunger during the short gap

The Overlap Approach

Some providers may consider a shorter transition period.

This may involve starting Zepbound a few days after the final Wegovy dose.

Potential benefit:

• Less interruption in appetite control

Potential risks:

• Increased nausea

• More digestive side effects

• Difficulty determining which medication caused symptoms

Most patients do better with a cautious transition.

Step 3: Start Zepbound at the Recommended Starting Dose

Even if someone was taking Wegovy 2.4 mg, the typical approach is to begin Zepbound at 2.5 mg weekly.

This starting dose is designed to:

• Test tolerance

• Reduce side effects

• Allow the body to adjust to tirzepatide

Starting too aggressively can increase nausea, vomiting, diarrhea, and other digestive issues.

Step 4: Increase the Dose Gradually

A common titration schedule includes:

Time Period

Dose

Weeks 1–4

2.5 mg

Weeks 5–8

5 mg

Weeks 9–12

7.5 mg

Weeks 13–16

10 mg

Weeks 17–20

12.5 mg if needed

Week 21+

15 mg if appropriate

The dose should increase based on:

• Weight-loss progress

• Side effects

• Appetite control

• Patient goals

Not everyone needs the highest dose.

Wegovy vs Zepbound Side Effect Comparison

Both medications can cause similar digestive side effects because they affect the same general hormone pathway.

Side Effect

Wegovy 2.4 mg

Zepbound 10 mg

Nausea

Higher frequency

Moderate frequency

Diarrhea

More common

Slightly lower

Constipation

More common

Less common

Injection reactions

Similar

Similar

Some patients who experience constipation on Wegovy report improvement after switching to Zepbound.

However, patients who experience severe nausea on one medication may still experience nausea on the other.

Three Common Patient Responses After Switching

Patients often fall into one of three categories after moving from Wegovy to Zepbound.

1. Strong Responders

These patients may notice:

• Better appetite control

• Continued weight loss

• Improved metabolic markers

• Ability to reach maintenance doses comfortably

Many reach effective doses between 7.5 mg and 10 mg.

2. Limited Responders

Some patients may experience:

• Minimal additional weight loss

• A continued plateau

• Little difference compared with Wegovy

In these cases, other factors should be reviewed, including:

• Sleep quality

• Thyroid function

• Hormonal conditions

• Medication-related weight gain

3. Patients Who Struggle With Side Effects

Some individuals may develop:

• Persistent nausea

• Vomiting

• Digestive discomfort

These patients may benefit from:

• Slower dose increases

• Longer time at each dose

• Reconsidering the original medication

When Switching From Wegovy to Zepbound Makes Sense

A switch may be reasonable when:

Weight loss has stalled

If someone has reached the maximum Wegovy dose and has stopped losing weight despite good adherence, another medication option may be considered.

Insurance coverage changes

Sometimes patients switch because one medication becomes more affordable or accessible.

Side effects affect quality of life

Different medications may produce different experiences for different people.

When Switching May Not Be the Best Choice

Switching may not be necessary if:

• Wegovy is still producing steady weight loss

• Side effects are manageable

• The patient is close to their goal weight

• The medication is affordable and covered

A medication change always comes with a new adjustment period.

Important Mistakes to Avoid During Conversion

Mistake 1: Using Fixed Dose Charts

A simple chart saying one Wegovy dose equals one Zepbound dose can be misleading.

Clinical response matters more than matching numbers.

Mistake 2: Starting Too High

Beginning with a high Zepbound dose increases side-effect risk.

Mistake 3: Expecting Immediate Results

The body needs time to adjust after switching medications.

Mistake 4: Ignoring Lifestyle Factors

Medication works best when combined with:

• Adequate protein intake

• Strength training

• Sleep improvement

• Sustainable eating habits

Final Thoughts: Finding the Right Wegovy to Zepbound Transition Strategy

There is no perfect Wegovy-to-Zepbound conversion formula because these medications are designed differently. While clinical trials provide useful comparisons, they cannot predict exactly how one person will respond after switching.

For many patients, Zepbound may offer stronger average weight-loss results because of its dual GIP and GLP-1 action. However, the best medication is the one that provides effective weight management with acceptable side effects and fits the patient’s healthcare situation.

A successful transition requires patience, careful dose adjustment, and ongoing communication with a healthcare provider. The goal is not simply switching medications — it is finding a long-term treatment approach that supports sustainable health improvements.